Novartis nears U.S. listing that could ease a merger

Article Abstract:

Novartis AG is close to completing the listing of its shares on the New York Stock Exchange. The move could lead to a major purchase or merger on the part of the company.

Novartis AG, New York Stock Exchange Inc.

---

Hoechst's vital signs get stronger

Article Abstract:

Hoechst Marion Roussel is trying its best to return to profitability. Industry experts anticipate Hoechst AG's subsidiary to release new medicines in a move to boost its sales to double digits by the start of the next decade. Hoechst Marion CEO Richard Markham stated that if everything goes as he expects, things will flow smoothly for the company. Hoechst Marion used to be the world's leading pharmaceutical firm in the early 1970s and continued to be successful until the time came when it failed to deliver profitability gains.

Comment:

Is trying its best to return to profitability

Hoechst Marion Roussel Inc., Article

---

Centocor shares drop 9.7% on news of side-effects of Crohn's disease drug

Article Abstract:

Centocor Inc. saw its share value decline by 9.7% following the company's statement that its Crohn's disease drug had serious side-effects. Centocor said that it had cautioned doctors that several users had complained of negative reactions after taking the Remicade drug. The drug had recently won approval as the first treatment of the inflammation of the intestine. Remicade was also being put through late-stage testing for rheumatoid arthritis.

Comment:

Share value declines 9.7% following the co's statement that its Crohn's disease drug had serious side-effects

Product standards, safety, & recalls, Pharmaceutical preparations, Securities prices, Antiinflammatory Drugs, Abstract, Anti-inflammatory agents, Centocor Inc., CNTO

Similar abstracts:

• Abstracts: Investors interested in Hoechst consider the effects of merger. Merck's fortunes hinge on success of diabetes drug
• Abstracts: DaimlerChrysler's U.S. sales rose 5% in 1999 on Jeep unit's strength. Passenger-car sales rose 10.4% in May in Western Europe
• Abstracts: Scor's U.S. unit reports net loss of $30 million. Scor's revenue rose last year. Insurers face claims flood after storms
• Abstracts: Peugeot's 1st-half sales put it on track to hit target. Sales of new cars in Europe likely to show a surge. Strong sales are predicted for Peugeot
• Abstracts: Motorola again scales back fourth-quarter profit and sales. Solectron warns of shortfall as demand remains sluggish

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.